TY - JOUR T1 - Effect of type and dosage of newly prescribed inhaled corticosteroids on obstructive lung disease and pneumonia hospitalisations in older individuals with asthma, COPD or both: a retrospective study of health administrative data JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02585-2020 VL - 57 IS - 1 SP - 2002585 AU - Tetyana Kendzerska AU - Shawn D. Aaron AU - Teresa To AU - Chris Licskai AU - Matthew B. Stanbrook AU - Mary-Ellen Hogan AU - Wan C. Tan AU - Jean Bourbeau AU - Andrea S. Gershon A2 - , Y1 - 2021/01/01 UR - http://erj.ersjournals.com/content/57/1/2002585.abstract N2 - The safety and risk–benefit profiles associated with different types and dosages of inhaled corticosteroids (ICS) in older individuals with asthma and COPD remain unknown [1, 2]. Limited evidence suggests that adults with asthma prescribed medium or high ICS doses are at risk of clinically important systemic side-effects that do not plateau with higher doses as efficacy outcomes do [3]. Older patients with COPD have been shown to have increased risk of pneumonia with both budesonide and fluticasone [4]; however, the risk seems greater with the latter [2, 4–6].This study suggested a less favourable safety-effectiveness profile for fluticasone compared to budesonide and other ICS in elderly individuals with asthma, COPD or both. Higher ICS dose was not associated with improved effectiveness in these populations. https://bit.ly/3iNdjkQThe severity of comorbidities at baseline was approximated using an aggregated score, the Johns Hopkins’ Aggregated Diagnosis Groups categories (The Johns Hopkins ACG® System, Version 10). We thank IMS Brogan Inc. for the use of their Drug Information Database. We acknowledge using data from Service Ontario and Immigration, Refugees and Citizenship Canada. ER -